Opinion

Video

HCC Staging: Improving Treatment Strategies

Author(s):

Richard Finn, MD,David James Pinato, MD, MRCP, PhD

The key opinion leaders discuss staging systems they use in clinical practice and their effectiveness in creating treatment algorithms, particularly with respect to Child-Pugh scores.

Related Videos
Richard Kim, MD, Moffitt Cancer Center
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Aaron Lisberg, MD, assistant clinical professor, medicine, University of California, Los Angeles School of Medicine
August 1st 2024

Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC

Aditya Bardia, MD, MPH, FASCO, of UCLA
October 15th 2024

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Saeho Chong, PhD, chief executive officer, Elevar Therapeutics
September 23rd 2024

NDA Resubmitted for Camrelizumab Plus Rivoceranib in Unresectable HCC

Lorenza Rimassa, MD
September 16th 2024

Durvalumab/Tremelimumab Sustains OS Benefit in Unresectable HCC